Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPRISA 012B
PACTR202003767867253Phase 1Unknown
- Sponsor
- CAPRISA
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of CAP256V2LS in human immunodeficiency virus infection (HIV) (4 arms), sponsored by CAPRISA. Primary endpoint: Safety and tolerability of CAP256V2LS. Status: unknown.
02
Drugs
CAP256V2LS
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on PACTR202003767867253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202003767867253.